Roche has announced a partnership with Moderna to use its Elecsys Anti-SARS-CoV-2 S antibody test in Moderna’s mRNA-1273 vaccine trials, according to Roche’s press release. Roche’s anti-SARS-CoV-2 antibody test detects antibodies against the SARS-CoV-2 spike protein, which is the target of Moderna’s vaccine.
- Measuring anti-RBD SARS-CoV-2 antibodies’ levels using Roche’s test will help gain valuable insights into the correlation between protection from vaccination and antibody levels.
- Roche was recently granted an emergency use authorization for its COVID-19 antibody test by the U.S. Food and Drug Administration.
Roche and Moderna stocks are currently gaining. RO: SWX is up 0.79%, MRNA: NASDAQ is up 2.04% on premarket
